SARS-COV-2 pandemic : Involvement of the hospital pharmacist in securing patient care
Copyright © 2023 Académie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved..
OBJECTIVES: In the context of the SARS-CoV-2 pandemic, hospital pharmacists supported the implementation of recommendations and ensured the safety of patient medication management. The aim of this study is to establish the interest of the involvement of the hospital pharmacist in this context by describing and comparing the activities carried out with patients with COVID-19 and those without.
METHODS: During the study period, data on clinical pharmacy activities with hospitalized patients were collected and analyzed: pharmaceutical analysis of prescriptions, participation in multi-professional consultation meetings (RCP) dedicated to COVID-19, and monitoring of adverse events.
RESULTS: The activities concerned 1483 patients, including 444 with COVID-19, resulting in 575 pharmaceutical interventions (PI). The main problems identified were overdoses, untreated indications, and drug-drug interactions (DDI). AMIs were significantly more common in patients with COVID-19, with 73.3% involving disease-specific therapies. Eleven PIs had a life-threatening impact, 189 a major impact. During the PCRs, 36 PIs were performed for 59% of the patients presented. A pharmacovigilance report was performed for a quarter of patients treated with hydroxychloroquine and 33% of patients treated with lopinavir/ritonavir.
CONCLUSIONS: This study demonstrates the value of involving hospital pharmacists in the drug management of patients with COVID-19, particularly with the evolution of available therapies and the implementation of vaccination, in order to reduce the spread of SARS-COV2 and limit the appearance of resistance.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:81 |
|---|---|
| Enthalten in: |
Annales pharmaceutiques francaises - 81(2023), 5 vom: 01. Sept., Seite 900-908 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Pandémie à SARS-COV-2 : implication du pharmacien hospitalier dans la sécurisation de la prise en charge des patients |
|---|
| Beteiligte Personen: |
Baudouin, Amandine [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Clinical pharmacy |
|---|
| Anmerkungen: |
Date Completed 25.08.2023 Date Revised 25.08.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.pharma.2023.04.005 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355906929 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355906929 | ||
| 003 | DE-627 | ||
| 005 | 20231226065334.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1016/j.pharma.2023.04.005 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1186.xml |
| 035 | |a (DE-627)NLM355906929 | ||
| 035 | |a (NLM)37086966 | ||
| 035 | |a (PII)S0003-4509(23)00046-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Baudouin, Amandine |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SARS-COV-2 pandemic |b Involvement of the hospital pharmacist in securing patient care |
| 246 | 3 | 3 | |a Pandémie à SARS-COV-2 : implication du pharmacien hospitalier dans la sécurisation de la prise en charge des patients |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.08.2023 | ||
| 500 | |a Date Revised 25.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Académie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a OBJECTIVES: In the context of the SARS-CoV-2 pandemic, hospital pharmacists supported the implementation of recommendations and ensured the safety of patient medication management. The aim of this study is to establish the interest of the involvement of the hospital pharmacist in this context by describing and comparing the activities carried out with patients with COVID-19 and those without | ||
| 520 | |a METHODS: During the study period, data on clinical pharmacy activities with hospitalized patients were collected and analyzed: pharmaceutical analysis of prescriptions, participation in multi-professional consultation meetings (RCP) dedicated to COVID-19, and monitoring of adverse events | ||
| 520 | |a RESULTS: The activities concerned 1483 patients, including 444 with COVID-19, resulting in 575 pharmaceutical interventions (PI). The main problems identified were overdoses, untreated indications, and drug-drug interactions (DDI). AMIs were significantly more common in patients with COVID-19, with 73.3% involving disease-specific therapies. Eleven PIs had a life-threatening impact, 189 a major impact. During the PCRs, 36 PIs were performed for 59% of the patients presented. A pharmacovigilance report was performed for a quarter of patients treated with hydroxychloroquine and 33% of patients treated with lopinavir/ritonavir | ||
| 520 | |a CONCLUSIONS: This study demonstrates the value of involving hospital pharmacists in the drug management of patients with COVID-19, particularly with the evolution of available therapies and the implementation of vaccination, in order to reduce the spread of SARS-COV2 and limit the appearance of resistance | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Clinical pharmacy | |
| 650 | 4 | |a Coronavirus | |
| 650 | 4 | |a Interventions pharmaceutiques | |
| 650 | 4 | |a Pharmacie clinique | |
| 650 | 4 | |a Pharmacist interventions | |
| 650 | 4 | |a SARS-CoV | |
| 650 | 4 | |a SARS-CoV2 | |
| 650 | 7 | |a RNA, Viral |2 NLM | |
| 700 | 1 | |a Guillemin, Marie-Delphine |e verfasserin |4 aut | |
| 700 | 1 | |a Rioufol, Catherine |e verfasserin |4 aut | |
| 700 | 1 | |a Ranchon, Florence |e verfasserin |4 aut | |
| 700 | 1 | |a Parat, Stéphanie |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annales pharmaceutiques francaises |d 1945 |g 81(2023), 5 vom: 01. Sept., Seite 900-908 |w (DE-627)NLM000046493 |x 0003-4509 |7 nnns |
| 773 | 1 | 8 | |g volume:81 |g year:2023 |g number:5 |g day:01 |g month:09 |g pages:900-908 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.pharma.2023.04.005 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 81 |j 2023 |e 5 |b 01 |c 09 |h 900-908 | ||